Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization
The requirements for effective cancer vaccines have gradually been worked out in experimental models over the past 15 years [1–3]. Many clinical trials in this field were initiated before this information was available or did not adhere to the methodologic requirements that had been found in the animal studies. As a consequence, there are several negative clinical investigations of active specific immunotherapy in which failure was a virtual certainty [4–6] when looked at in retrospect with regard to the requirements that have been identified in animal models. Some of the key requirements are as follows.
KeywordsBacillus Sarcoma Cyclophosphamide Allo Mycobacterium
Unable to display preview. Download preview PDF.
- 1.Bartiett GL, Zbar B (1972) Tumor-specific vaccine containing mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48: 1709–1726Google Scholar
- 2.Scott MT (1975) Potentiation of the tumor–specific immune response by Corynebacterium parvum. J Natl Can Inst 55: 65–72Google Scholar
- 9.Sahasrabudhe DM, deKernion JB, Pontes JE etal. (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Mod 5: 581–594Google Scholar
- 10.Neidhart JA, Gagen M, Young D, Wise H (1983) A randomized study of polymerized tumor antigen admixed with adjuvant for therapy of renal cancer. Proc Am Soc Clin Oncol 2: 49Google Scholar
- 11.Adler A, Gillon G, Lurie H etal. (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormone-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Resp Mod 6: 610–624Google Scholar
- 13.Hoover HC, Surdyke M, Dangel RB etal. (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 44: 1671–1676Google Scholar